-

11:41:05 AM

TNXP Stock News

TNXP - Tonix Pharmaceuticals Holding Corp

01/11/22 7:00 AM

Nasdaq : TNXP

clinical trial

Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2

RHEA-AI

negative

01/05/22 7:00 AM

Nasdaq : TNXP

conferences

Tonix Pharmaceuticals to Participate in Upcoming January Conferences

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate in the

RHEA-AI

neutral

01/04/22 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines

New Zinc Nanoparticle (ZNP) Technology Replaces the Lipid Nanoparticle (LNP) Technology Employed in Current mRNA COVID-19 Vaccines ZNP Technology Expected to Improve mRNA Vaccine Temperature Stability for Storage and Transport TNX-3700 is a ZNP mRNA COVID-19 Vaccine in Development in Collaboration

RHEA-AI

neutral

12/15/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Added to the Nasdaq Biotechnology Index

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the Nasdaq’s annual

RHEA-AI

neutral

12/14/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a

RHEA-AI

neutral

12/13/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers

TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers In Mouse Models, rTFF2 Detoxifies the Tumor Microenvironment, Allows Activation of Cancer-Killing CD8+T Cells and Limits Immune Evasion by Cancer

RHEA-AI

positive

11/23/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the

RHEA-AI

neutral

11/22/21 4:05 PM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage

RHEA-AI

neutral

11/15/21 7:00 AM

Nasdaq : TNXP

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,167,010 on November 9, 2021. The patent,

RHEA-AI

neutral

11/12/21 7:00 AM

Nasdaq : TNXP

conferences

Tonix Pharmaceuticals to Present at the Q4 Investor Summit

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the Q4

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

TNXP Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tonixpharma.com
CeoSeth Lederman
Security nameTonix Pharmaceuticals Holding Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees26
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address26 Main Street, Suite 101
StateNew Jersey
CityChatham
Zip07928
CountryUnited States
Phone12129809155

TNXP Description:

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.